Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2025-04-08 11:22
On the evening of April 7, Jiankangyuan released its 2024 annual report, showing annual operating revenue of 15.619 billion yuan, net profit attributable to shareholders of 1.387 billion yuan, net profit attributable to shareholders after deducting non-recurring gains and losses of 1.319 billion yuan, and net cash flow from operating activities of 3.636 billion yuan.
Time Posted：2025-04-02 13:25
With the increasing number of COPD (Chronic Obstructive Pulmonary Disease) patients globally, existing treatments face the dual challenges of efficacy and compliance. COPD is one of the leading causes of respiratory failure and death worldwide, and while existing treatments have made progress, they still fail to effectively address issues such as acute exacerbations and prolonged disease progression in patients. HealthGen Biotech, through technological innovation, is developing a PREP inhibitor. This breakthrough product will bring new hope to COPD patients while driving progress and development in the global COPD treatment field.
Time Posted：2025-03-26 09:39
Driven by the trend of innovative drugs accelerating towards mechanism upgrades and precise expansion of indications, HealthGen Pharma has begun to lay out a diversified innovation field beyond its main line of respiratory disease treatment. The company's R&D project targeting Nav1.8 sodium channel inhibitors for analgesia marks a significant extension in its chronic disease treatment chain, and also reflects its path choice of continuously deepening its multi-pipeline synergy strategy.
Time Posted：2025-03-19 10:24
Chronic obstructive pulmonary disease (COPD) is a prevalent chronic disease worldwide, significantly impacting patients' quality of life and placing a heavy burden on healthcare systems. Statistics indicate that there are over 300 million COPD patients globally, with over 100 million in China. However, due to low early diagnosis rates, many patients are diagnosed at an irreversible stage. With the development of precision medicine, innovative biologics are becoming a new direction in COPD treatment. HealthyGen Pharmaceuticals Group (600380.SH) is accelerating the research and development of TSLP monoclonal antibody and IL-4R monoclonal antibody, hoping to provide more effective treatment options for patients through scientific innovation and to promote the upgrading of COPD treatment methods.
Time Posted：2025-03-11 15:30
Against the backdrop of intensifying global public health challenges, China is accelerating the "Healthy China 2030" strategy to improve the overall health of its population and optimize its chronic disease management system. The agenda of the National People's Congress and the Chinese People's Political Consultative Conference in 2025 also focused on chronic disease prevention and control, optimization of primary-level medical resources, and the construction of the public health system, providing policy support for the innovative development of the pharmaceutical industry. As a leading domestic enterprise in the respiratory field, HealthGen Biotech Group is leveraging technological innovation to comprehensively develop a respiratory disease prevention and control system, contributing to national public health construction, and promoting the leading position of China's pharmaceutical industry in global competition.
Time Posted：2025-02-14 10:40
Recently, HealthGen Biotech Group was successfully included in S&P Global's Sustainability Yearbook 2025 (Global Edition) due to its outstanding performance in Environmental, Social, and Governance (ESG). This honor not only demonstrates HealthGen's continuous efforts and remarkable achievements in sustainable development but also signifies the company's leading position in ESG practices within the global pharmaceutical industry.
Influenza is coming! Deepseek reveals the secrets of Health Yuan's "Mapassive"
Time Posted：2025-02-13 08:40
Recently, influenza A virus has resurged and spread rapidly across the country, seriously affecting people's work and life. Common symptoms after infection include high fever, cough, and fatigue. Some patients even develop serious complications, putting considerable pressure on the medical system. Experts urge the public to be vigilant and seek medical attention early.
Time Posted：2025-01-26 17:00
In today's rapidly developing society, enterprises are not only the backbone of the economy, but also important players in fulfilling social responsibilities and promoting social progress. Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare"), as a large comprehensive pharmaceutical group in the pharmaceutical industry, has not only achieved remarkable results in R&D innovation and new drug pipelines, but also made significant contributions in social responsibility.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.